Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial
Titel:
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial
Auteur:
Cahn, Pedro Kaplan, Richard Sax, Paul E Squires, Kathleen Molina, Jean-Michel Avihingsanon, Anchalee Ratanasuwan, Winai Rojas, Evelyn Rassool, Mohammed Bloch, Mark Vandekerckhove, Linos Ruane, Peter Yazdanpanah, Yazdan Katlama, Christine Xu, Xia Rodgers, Anthony East, Lilly Wenning, Larissa Rawlins, Sandy Homony, Brenda Sklar, Peter Nguyen, Bach-Yen Leavitt, Randi Teppler, Hedy